![]() |
||||
|
||||
![]() |
||||
|
![]() |
|||||||||||
|
![]() |
Dear Subscriber As part of our on-going series of company profiles, we introduce you to Celsion Corporation. This Maryland-based biotech is emerging as a leader in developing nanomedicines for heat-activated targeted drug delivery. Through clinical trials around the world and a major collaboration with Royal Philips Electronics, Celsion is evaluating its first product, ThermoDox, as a treatment for several of the most lethal and difficult to treat cancers. Potential indications include primary liver cancer, recurrent chest wall breast cancer, metastatic bone cancer, and pancreatic cancer. This month’s other stories provide an update on our Research Awards Program, the Foundation’s upcoming international Symposium and its support of other industry meetings.
|
![]() |
|||
The heat is on at Celsion | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
Laurent Leksell and Kullervo Hynynen will be featured speakers at 2nd International MR-guided FUS Symposium | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
FUSF Research Awards Program accepting proposals | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
FUSF supporting three upcoming industry meetings |
|||
![]() |
|
![]() |
|
![]() |
![]() |
![]() |